Skip to content

Yuichiro Ohe

Université Paris-Sud

2 papers in the Anchorcite directory, published between 2009 and 2017, cited 13,995 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Busayamas Chewaskulyong · 2 papers
  • Tony S.K. Mok · 1 paper
  • Yi-Long Lung Cancer Wu · 1 paper
  • Sumitra Thongprasert · 1 paper
  • Da-Tong Chu · 1 paper
  • Nagahiro Saijo · 1 paper
  • Patrapim Sunpaweravong · 1 paper
  • Baohui Han · 1 paper

Papers

  1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine · 2009 · 8,355 citations

    BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer. METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced…

  2. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations

    BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell…

Metadata from OpenAlex (CC0).